OncoZenge AB (publ) ONCOZ.ST
ONCOZ.ST
OncoZenge AB (publ) ACOU.ST
AcouSort AB (publ) SIMRIS-B.ST
Simris Alg AB (publ) SPRINT.ST
Sprint Bioscience AB (publ) LPGO.ST
Lipigon Pharmaceuticals AB (publ) NEWBRY.ST
Newbury Pharmaceuticals AB (publ) EXPRS2.ST
ExpreS2ion Biotech Holding AB (publ) PILA.ST
Pila Pharma AB (publ) MODTX.ST
Modus Therapeutics Holding AB (publ) SPEC.ST
SpectraCure AB (publ)
OncoZenge AB (publ) ACOU.ST
AcouSort AB (publ) SIMRIS-B.ST
Simris Alg AB (publ) SPRINT.ST
Sprint Bioscience AB (publ) LPGO.ST
Lipigon Pharmaceuticals AB (publ) NEWBRY.ST
Newbury Pharmaceuticals AB (publ) EXPRS2.ST
ExpreS2ion Biotech Holding AB (publ) PILA.ST
Pila Pharma AB (publ) MODTX.ST
Modus Therapeutics Holding AB (publ) SPEC.ST
SpectraCure AB (publ)
Performance
| Periode | ONCOZ.ST | ACOU.ST | SIMRIS-B.ST | SPRINT.ST | LPGO.ST | NEWBRY.ST | EXPRS2.ST | PILA.ST | MODTX.ST | SPEC.ST |
|---|---|---|---|---|---|---|---|---|---|---|
| 6M | 22.15 % | -22.61 % | 17.01 % | 6.06 % | 55.29 % | -24.92 % | -11.18 % | -30.25 % | -64.65 % | -88.48 % |
| YTD | 60.45 % | -74.36 % | 12.94 % | -52.70 % | 9.85 % | -29.83 % | -29.02 % | -44.24 % | -74.49 % | -90.97 % |
| 1Y | -41.98 % | -79.36 % | 38.75 % | -64.82 % | -28.84 % | -38.25 % | -48.14 % | -56.37 % | -68.38 % | -88.74 % |
| 3Y | 3.27 % | -80.91 % | -57.96 % | -33.33 % | -89.88 % | -51.95 % | -96.86 % | -34.90 % | -77.55 % | -94.74 % |
| 5Y | -53.58 % | -86.01 % | -89.19 % | -90.75 % | -98.70 % | -80.40 % | -96.30 % | -75.19 % | -91.45 % | -98.80 % |
| 10Y | -53.58 % | -86.01 % | -99.04 % | -98.22 % | -98.70 % | -80.40 % | -91.82 % | -75.19 % | -91.45 % | -85.18 % |
| From the beginning | -53.58 % | -86.01 % | -99.04 % | -95.33 % | -98.70 % | -80.40 % | -91.82 % | -75.19 % | -91.45 % | -86.70 % |